Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

10 Jul 2018 13:36

RNS Number : 1932U
Diurnal Group PLC
10 July 2018
 

10 July 2018

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Grant of Deferred Share Awards

Director and PDMR Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following deferred bonus share awards over ordinary shares of 5 pence ("Ordinary Shares") in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR") in respect of the bonus due for the financial year ended 30 June 2018:

 

PDMR

Total number of shares under award

Type of award

Martin Whitaker

35,580

Deferred bonus share

Richard Bungay

22,682

Deferred bonus share

Richard Ross

9,381

Deferred bonus share

 

Under the rules of the Plan, 50% of the annual bonus payable to the senior management team are settled in deferred share bonus awards. Annual bonuses are payable at the sole discretion of the Remuneration Committee on the basis set out in the 2017 annual report. The bonus performance criteria for 2017/2018 included clinical and commercial milestones. The deferred bonus share awards will ordinarily vest on the first anniversary of their grant subject to the grantee's continued service. The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

This notification is made in accordance with the Market Abuse Regulation.

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: James Stearns

Cantor Fitzgerald Europe (Joint Broker)

+44 (0) 20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot

Healthcare Equity Sales: Andrew Keith

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

Deferred bonus award over 35,580 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

35,580

d)

 

Aggregated information

- Aggregated volume

35,580

- Price

£nil

e)

 

Date of the transaction

 

10 July 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 22,682 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

22,682

d)

 

Aggregated information

- Aggregated volume

22,682

- Price

£nil

e)

 

Date of the transaction

 

10 July 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Ross

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Scientific Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 9,381 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

9,381

d)

 

Aggregated information

- Aggregated volume

9,381

- Price

£nil

e)

 

Date of the transaction

 

10 July 2018

f)

 

Place of the transaction

 

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSFDFESFASEDW
Date   Source Headline
12th May 20213:44 pmRNSDirector Dealings
12th May 20211:58 pmRNSHolding(s) in Company
12th May 202112:08 pmRNSHolding(s) in Company
12th May 20217:00 amRNSAgreement with Citrine Medicine for Efmody
11th May 20214:43 pmRNSHolding(s) in Company
11th May 20213:25 pmRNSHolding(s) in Company
10th May 202110:26 amRNSResult of General Meeting
23rd Apr 20217:00 amRNSGrant of second European Patent for Alkindi
21st Apr 202111:51 amRNSResult of Placing and Subscription
21st Apr 20217:00 amRNSProposed Placing, Subscription and Open Offer
15th Apr 20219:49 amRNSRequest for Efmody Orphan Designation withdrawn
26th Mar 20212:06 pmRNSSecond Price Monitoring Extn
26th Mar 20212:00 pmRNSPrice Monitoring Extension
26th Mar 202111:57 amRNSEMA issues positive opinion for second product
15th Mar 20217:00 amEQSEdison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10th Mar 20219:44 amRNSHolding(s) in Company
8th Mar 20215:34 pmRNSHolding(s) in Company
25th Feb 20217:15 amEQSHardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)
24th Feb 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
23rd Feb 20217:01 amRNSInterim Results
23rd Feb 20217:00 amRNSChronocort agreement with Consilient for Nordics
2nd Feb 20217:01 amRNSChronocort results published in JCEM
27th Jan 20219:00 amRNSPrice Monitoring Extension
27th Jan 20217:00 amRNSChina licencing agreement with Citrine for Alkindi
14th Jan 20217:01 amRNSBusiness and trading update
14th Jan 20217:00 amRNSAgreement with Eton for Alkindi extended to Canada
13th Jan 202110:07 amRNSAgreement with Er-Kim for distribution in Turkey
12th Jan 20217:00 amRNSChronocort MAA Submitted to the UK MHRA
11th Jan 20217:00 amRNSGrant of European Patent for Chronocort
22nd Dec 20203:29 pmRNSIssue of LTIP Awards
11th Dec 20202:02 pmRNSExercise of Options, Issue of Equity and TVR
23rd Nov 20207:00 amRNSExercise of Options, Issue of Equity and TVR
20th Nov 202012:06 pmRNSResult of Annual General Meeting
20th Nov 20207:00 amRNSGrant of European Patent for Alkindi
10th Nov 20207:00 amRNSNotice of Interim Results
2nd Nov 20204:47 pmRNSHolding(s) in Company
30th Oct 202011:34 amRNSHolding(s) in Company
30th Oct 20208:37 amRNSHolding(s) in Company
29th Oct 202010:30 amRNSHolding(s) in Company
29th Oct 20209:25 amRNSDirector Dealings
28th Oct 202012:49 pmRNSResult of General Meeting and Open Offer
21st Oct 20207:00 amRNSMAA for Alkindi submitted to Swissmedic
19th Oct 20207:00 amRNSVesting of LTIP awards
9th Oct 202010:37 amRNSResult of Placing, Open Offer and Notice of GM
9th Oct 20207:00 amRNSProposed Placing and Open Offer
8th Oct 20202:28 pmRNSPosting of Annual Report and AGM Notice
30th Sep 20204:41 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20208:15 amEQSHardman & Co Research: Diurnal (DNL): And then there were three
30th Sep 20207:00 amRNSAlkindi Sprinkle approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.